Now we know why yesterday's volume ahead of news!
Nice to see Lance lining up the ducks.
February 02 2022 - 08:00AM
GlobeNewswire Inc.
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® Program. The notice of allowance was issued on January 26, 2022 and is related to a new patent application not previously announced.
Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes from human brown adipose-derived stem cells. The combination of scaffolds as a delivery system and brown adipose derived stem cells provides the ability to deliver metabolically active cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders.
“We continue to see success developing a comprehensive global patent portfolio for ThermoStem® and this latest notice of allowance further strengthens our overall IP position in using scaffolds as a delivery system." said Lance Alstodt, the Company’s CEO "The claims of this application are the result of BioRestorative’s expertise in applying cell therapy to treat metabolic disorders. They underscore the potential value of ThermoStem® as a novel treatment for diseases such as diabetes and obesity, which represent major unmet needs."
